Looking for new treatments: Meditech and LEI team up
22 May, 2002 by Melissa TrudingerMeditech Research and the Lion's Eye Institute (LEI) have signed a licence agreement allowing LEI to use patents owned by Meditech in developing products for the prevention and treatment of eye diseases.
ASX or Nasdaq? Acrux investigates listing opportunities
22 May, 2002 by Tanya HollisTransdermal drug delivery company Acrux is planning a public listing in the next year but is yet to decide whether it will be on an Australian or United States bourse.
The wonderful world of cloning
22 May, 2002 by Tanya HollisSince the world's most famous cloned sheep was unveiled to a gob-smacked science community, the race has been on to build on the work.
Our world-class clones (no bull)
22 May, 2002 by Tanya HollisOn the global stage, the contribution of Australia and New Zealand to the livestock cloning arena is world class, which is only natural given the region's strong tradition in agriculture.
A year after listing, Cellestis reflects on achievements
22 May, 2002 by Melissa TrudingerCellestis is a quiet achiever in the Australian biotechnology scene.
Positive trial results for Sirtex
21 May, 2002 by Daniella GoldbergSydney-based company Sirtex Medical has completed Phase II/III clinical trials that showed over 90 per cent of liver cancer patients successfully responded to its radioactive SIR-Spheres treatment.
Virax appoints new R&D head
21 May, 2002 by Tanya HollisImmune-based therapies developer Virax Holdings (ASX: VHL) has appointed a British scientist to head its vector research and process development.
South Australian feature: Biotechnology in the field
21 May, 2002 by Melissa TrudingerThe South Australian Research and Development Institute (SARDI) is part of South Australia's Department of Primary Industries and Resources.
Solution in sight for frozen pig embryo riddle
20 May, 2002 by Pete YoungA small Australian research team believes it is poised to solve a 25-year-old riddle and open new horizons for the global pig industry.
MicroMedical loss 'expected'
17 May, 2002 by Tanya HollisArtificial heart developer MicroMedical Industries has forecast a larger full-year loss than it experienced last year, but said it was an expected outcome.
Eiffel partners with UK drug delivery specialist
17 May, 2002 by Tanya HollisMelbourne bioengineering company Eiffel Technologies has entered a research partnership with London-based Amarin Corporation to manufacture slow-release, sub-micron sized drugs.
Tasmanian feature: GM ban impacts on local bio
17 May, 2002 by Tanya Hollis and Melissa TrudingerA moratorium by the Tasmanian government on genetically modified organisms has the potential to seriously impact future biotechnology research in the state, especially in the agricultural sector.
Meditech's contribution to cancer fight
17 May, 2002 by Daniella GoldbergMeditech Research has completed Phase I clinical trials of its anti-cancer therapy HyDox, indicating the treatment is safe for patients with breast cancer, renal carcinoma, sarcoma and prostate cancer.
Ambri hopes its tech can prevent endoscopy injury
16 May, 2002 by Daniella GoldbergAmbri is looking to expand the potential applications of its critical care diagnostic system, SensiDx System, enabling surgeons to rapidly detect bowel damage that can occur during an operation.
Premier Bionics' IPO set to make target
16 May, 2002 by Tanya HollisDevice and diagnostics investment company Premier Bionics is on track to close its initial public offering tomorrow (May 17) oversubscribed.
